Oil Profits Surge: Buy the Cash Flow, Not the War Bet

http://wealthcreation.clubLeave a comment

📌 Update: Oil stocks warrant selective buying, not a blanket bet on prolonged war. Higher energy prices, refining margins up three- to fourfold and trading gains are boosting earnings. IEA chief Fatih Birol expects energy markets to remain disrupted through 2027. We favour companies that generate resilient cash flow at lower oil prices, treating prolonged disruption as upside—not a prerequisite for returns

🔷 Featured allocation: US$80,000 | Four years  


At an assumed annual return of 12%, compounded annually, US$80,000 would grow to approximately US$125,881.55—a potential gain of US$45,881.55.


Explore Our Investment Plans


🔴 US$250,000+ | Five-year term  
Target: 0.5% monthly income plus 15% annually.


At an assumed annual return of 15% PLUS 0.5% per month compounded annually, US$250,000 would grow to approximately US$678,254.86—a potential gain of US$427,254.86


🟡 US$100,000+ | Two-year term  
Target: 0.5% monthly income plus 11% annually.


At an assumed annual return of 11% PLUS 0.5% per month compounded annually, US$100,000 would grow to approximately US$138,877.36—a potential gain of US$38,877.36


🟠 US$50,000 | Four-year term  
Proposed annual return: 9%.


At an assumed annual return of 9% US$50,000 would grow to approximately US$70,579.08—a potential gain of US$38,877.36


🔵 $1M | 2 years – Targeted: 0.5% monthly income plus 21% annually. 


At an assumed annual return of 21% PLUS 0.5% per month compounded annually, US$1M would grow to approximately US$1,516.706 —a potential gain of US$516,706


WhatsApp: bit.ly/Alpha-Binwani-Capital


Website: alphabinwanicapital.com


LinkedIn: bit.ly/Alpha-Binwani-Capital-LinkedIn


Newsletter: bit.ly/FreeAlphaNewsletter


#OilStocks #EnergyStocks #OilAndGas #EnergyMarkets #OilPrices #BrentCrude #EarningsSeason #CashFlow #Dividends #ValueInvesting #SelectiveInvesting #GeopoliticalRisk #EnergySecurity #InvestmentStrategy

Sanofi Smashes Earnings Estimates, Raises Outlook as Dupixent Sales Soar

http://wealthcreation.clubLeave a comment
‼️ BREAKING: Sanofi (EPA:SASY) reported stronger-than-expected third-quarter results and raised its annual outlook, driven by robust Dupixent demand. Business EPS, excluding one-off charges, rose 22% to €3.55, beating estimates of €2.79, while sales climbed 16.2% to €14.44 billion. Dupixent sales surged nearly 35% to €5.7 billion, above consensus of roughly €5 billion, while new drug launches grew 31.4% to €1.4 billion, helping offset a 6.6% decline in vaccine sales to €3.2 billion.